ipilimumab
bms
['melanoma', 'ipilimumab']
 #esmo2022 bringing #til therapy into second line for melanoma. randomized study with pfs benefit vs ipilimumab 
Chief of Research and Immunotherapy  •  ImmunoOncology  •  Phase I  Clinical Trials  •  Melanoma  •  Cutaneous Oncology